Madrigal Pharmaceuticals (MDGL) Non-Current Debt (2010 - 2026)
Madrigal Pharmaceuticals (MDGL) posted quarterly Non-Current Debt of $340.8 million for Q2 2026, up 187.89% year-over-year from $118.4 million in Q2 2025, and little changed quarter-over-quarter from $340.3 million in Q1 2026.
Madrigal Pharmaceuticals (MDGL) Non-Current Debt (2010 - 2026) Analysis & Trends
Madrigal Pharmaceuticals (MDGL) has reported Non-Current Debt for 11 consecutive years, with $340.8 million the latest figure, recorded in Q2 2026.
- In Q2 2026, Non-Current Debt rose 187.89% year-over-year to $340.8 million; the TTM figure through Jun 2026 stood at $340.8 million (up 187.89% YoY), while the FY2025 annual figure was $339.9 million, up 189.09% from the prior year.
- Non-Current Debt steadied at $340.8 million in Q2 2026 per MDGL's latest filing, from $340.3 million in the prior quarter.
- Across five years, Non-Current Debt topped out at $340.8 million in Q2 2026 and bottomed at $49.3 million in Q4 2022.
- Historically, Non-Current Debt has averaged $162.2 million across 5 years, with a median of $117.6 million in 2024.
- Annual changes were most pronounced in 2024 — Non-Current Debt fell 21.36% — and 2025, when it jumped 190.17%.
- Madrigal Pharmaceuticals' Non-Current Debt stood at $49.3 million in 2022, then surged by 134.29% to $115.5 million in 2023, then increased by 1.81% to $117.6 million in 2024, then soared by 189.09% to $339.9 million in 2025, then increased by 0.27% to $340.8 million in 2026.
- Business Quant data shows MDGL's Non-Current Debt at $340.8 million in Q2 2026, $340.3 million in Q1 2026, and $339.9 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.99 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 882.16 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 8.96 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 546.77 Mn |
| 10 | Madrigal Pharmaceuticals | 14.79 Bn | 13.95 Bn | - | 340.79 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 340.79 Mn |
| Mar 31, 2026 | 340.33 Mn |
| Dec 31, 2025 | 339.88 Mn |
| Sep 30, 2025 | 339.75 Mn |
| Jun 30, 2025 | 118.38 Mn |
| Mar 31, 2025 | 118.01 Mn |
| Dec 31, 2024 | 117.57 Mn |
| Sep 30, 2024 | 117.09 Mn |
| Jun 30, 2024 | 116.61 Mn |
| Mar 31, 2024 | 116.14 Mn |
| Dec 31, 2023 | 115.48 Mn |
| Sep 30, 2023 | 148.89 Mn |
| Jun 30, 2023 | 99.25 Mn |
| Mar 31, 2023 | 113.70 Mn |
| Dec 31, 2022 | 49.29 Mn |
| Sep 30, 2022 | 48.98 Mn |
| Jun 30, 2022 | 48.67 Mn |
| Jun 30, 2015 | 10,000.00 |
| Mar 31, 2015 | 2.30 Mn |
| Dec 31, 2014 | 4.61 Mn |